(RGEN) Repligen - Ratings and Ratios
Exchange: NASDAQ •
Country: United States •
Currency: USD •
Type: Common Stock •
ISIN: US7599161095
Protein A Ligands, Chromatography Columns, Filtration Systems, Process Analytics
EPS (Earnings per Share)
Revenue
Dividends
Currently no dividends paid| Risk via 5d forecast | |
|---|---|
| Volatility | 46.3% |
| Value at Risk 5%th | 68.7% |
| Relative Tail Risk | -9.82% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | 0.00 |
| Alpha | -28.21 |
| CAGR/Max DD | -0.12 |
| Character TTM | |
|---|---|
| Hurst Exponent | 0.396 |
| Beta | 1.458 |
| Beta Downside | 1.301 |
| Drawdowns 3y | |
|---|---|
| Max DD | 47.75% |
| Mean DD | 24.80% |
| Median DD | 24.16% |
Description: RGEN Repligen January 07, 2026
Repligen Corporation (NASDAQ:RGEN) is a life-sciences tools provider that designs, manufactures, and sells bioprocessing technologies worldwide, including Protein A affinity ligands, cell-culture growth factors, pre-packed chromatography columns, filtration systems (e.g., XCell ATF, TangenX cassettes), and process-analytics instruments such as SoloVPE. Its customers span biopharma manufacturers, contract development organizations, and diagnostic firms, and the company maintains a collaboration with Navigo Proteins to co-develop new affinity ligands.
Key recent metrics: FY 2023 revenue reached roughly $1.12 billion, up about 13 % year-over-year, driven by strong demand for single-use chromatography and filtration solutions; gross margin hovered near 70 %, reflecting the high-value nature of its consumables. The global bioprocessing market is projected to grow at a CAGR of ~9 % through 2028, fueled by the expanding pipeline of biologics and the shift toward continuous manufacturing, both of which underpin Repligen’s growth outlook.
For a deeper quantitative view, you might explore ValueRay’s analyst toolkit to assess how these trends translate into valuation scenarios.
Piotroski VR‑10 (Strict, 0-10) 3.5
| Net Income: 1.74m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.04 > 0.02 and ΔFCF/TA -0.99 > 1.0 |
| NWC/Revenue: 136.4% < 20% (prev 165.6%; Δ -29.23% < -1%) |
| CFO/TA 0.04 > 3% & CFO 130.9m > Net Income 1.74m |
| Net Debt (-59.9m) to EBITDA (133.8m): -0.45 < 3 |
| Current Ratio: 8.36 > 1.5 & < 3 |
| Outstanding Shares: last quarter (56.5m) vs 12m ago -0.74% < -2% |
| Gross Margin: 45.38% > 18% (prev 0.47%; Δ 4491 % > 0.5%) |
| Asset Turnover: 24.60% > 50% (prev 21.83%; Δ 2.78% > 0%) |
| Interest Coverage Ratio: 0.59 > 6 (EBITDA TTM 133.8m / Interest Expense TTM 44.3m) |
Altman Z'' 3.27
| A: 0.33 (Total Current Assets 1.10b - Total Current Liabilities 131.1m) / Total Assets 2.92b |
| B: 0.15 (Retained Earnings 443.0m / Total Assets 2.92b) |
| C: 0.01 (EBIT TTM 26.1m / Avg Total Assets 2.88b) |
| D: 0.52 (Book Value of Equity 439.4m / Total Liabilities 840.6m) |
| Altman-Z'' Score: 3.27 = A |
Beneish M -2.89
| DSRI: 1.01 (Receivables 149.0m/129.0m, Revenue 707.9m/617.9m) |
| GMI: 1.04 (GM 45.38% / 47.04%) |
| AQI: 1.07 (AQ_t 0.52 / AQ_t-1 0.48) |
| SGI: 1.15 (Revenue 707.9m / 617.9m) |
| TATA: -0.04 (NI 1.74m - CFO 130.9m) / TA 2.92b) |
| Beneish M-Score: -2.89 (Cap -4..+1) = A |
What is the price of RGEN shares?
As of January 29, 2026, the stock is trading at USD 160.05 with a total of 438,796 shares traded.
Over the past week, the price has changed by -5.84%, over one month by -3.43%, over three months by +5.59% and over the past year by -8.14%.
Over the past week, the price has changed by -5.84%, over one month by -3.43%, over three months by +5.59% and over the past year by -8.14%.
Is RGEN a buy, sell or hold?
Repligen has received a consensus analysts rating of 4.26.
Therefore, it is recommended to buy RGEN.
- StrongBuy: 10
- Buy: 4
- Hold: 5
- Sell: 0
- StrongSell: 0
What are the forecasts/targets for the RGEN price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 190.9 | 19.3% |
| Analysts Target Price | 190.9 | 19.3% |
| ValueRay Target Price | 161.7 | 1% |
RGEN Fundamental Data Overview January 29, 2026
P/E Trailing = 8181.5005
P/E Forward = 87.7193
P/S = 13.0117
P/B = 4.4139
P/EG = 2.59
Revenue TTM = 707.9m USD
EBIT TTM = 26.1m USD
EBITDA TTM = 133.8m USD
Long Term Debt = 537.9m USD (from longTermDebt, last quarter)
Short Term Debt = 19.3m USD (from shortTermDebt, last quarter)
Debt = 688.9m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = -59.9m USD (from netDebt column, last quarter)
Enterprise Value = 9.15b USD (9.21b + Debt 688.9m - CCE 748.7m)
Interest Coverage Ratio = 0.59 (Ebit TTM 26.1m / Interest Expense TTM 44.3m)
EV/FCF = 85.94x (Enterprise Value 9.15b / FCF TTM 106.5m)
FCF Yield = 1.16% (FCF TTM 106.5m / Enterprise Value 9.15b)
FCF Margin = 15.04% (FCF TTM 106.5m / Revenue TTM 707.9m)
Net Margin = 0.25% (Net Income TTM 1.74m / Revenue TTM 707.9m)
Gross Margin = 45.38% ((Revenue TTM 707.9m - Cost of Revenue TTM 386.6m) / Revenue TTM)
Gross Margin QoQ = 53.24% (prev 49.98%)
Tobins Q-Ratio = 3.13 (Enterprise Value 9.15b / Total Assets 2.92b)
Interest Expense / Debt = 3.98% (Interest Expense 27.4m / Debt 688.9m)
Taxrate = 12.86% (2.20m / 17.1m)
NOPAT = 22.8m (EBIT 26.1m * (1 - 12.86%))
Current Ratio = 8.36 (Total Current Assets 1.10b / Total Current Liabilities 131.1m)
Debt / Equity = 0.33 (Debt 688.9m / totalStockholderEquity, last quarter 2.08b)
Debt / EBITDA = -0.45 (Net Debt -59.9m / EBITDA 133.8m)
Debt / FCF = -0.56 (Net Debt -59.9m / FCF TTM 106.5m)
Total Stockholder Equity = 2.03b (last 4 quarters mean from totalStockholderEquity)
RoA = 0.06% (Net Income 1.74m / Total Assets 2.92b)
RoE = 0.09% (Net Income TTM 1.74m / Total Stockholder Equity 2.03b)
RoCE = 1.02% (EBIT 26.1m / Capital Employed (Equity 2.03b + L.T.Debt 537.9m))
RoIC = 0.89% (NOPAT 22.8m / Invested Capital 2.56b)
WACC = 10.75% (E(9.21b)/V(9.90b) * Re(11.29%) + D(688.9m)/V(9.90b) * Rd(3.98%) * (1-Tc(0.13)))
Discount Rate = 11.29% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 100.0 | Cagr: 0.63%
[DCF Debug] Terminal Value 72.87% ; FCFF base≈116.4m ; Y1≈143.6m ; Y5≈244.5m
Fair Price DCF = 47.99 (EV 2.64b - Net Debt -59.9m = Equity 2.70b / Shares 56.3m; r=10.75% [WACC]; 5y FCF grow 25.0% → 2.90% )
EPS Correlation: -75.41 | EPS CAGR: -53.93% | SUE: -3.52 | # QB: 0
Revenue Correlation: -40.77 | Revenue CAGR: 0.33% | SUE: 2.60 | # QB: 3
EPS next Quarter (2026-03-31): EPS=0.44 | Chg30d=-0.001 | Revisions Net=+0 | Analysts=15
EPS next Year (2026-12-31): EPS=2.08 | Chg30d=-0.006 | Revisions Net=-1 | Growth EPS=+24.4% | Growth Revenue=+12.5%
P/E Forward = 87.7193
P/S = 13.0117
P/B = 4.4139
P/EG = 2.59
Revenue TTM = 707.9m USD
EBIT TTM = 26.1m USD
EBITDA TTM = 133.8m USD
Long Term Debt = 537.9m USD (from longTermDebt, last quarter)
Short Term Debt = 19.3m USD (from shortTermDebt, last quarter)
Debt = 688.9m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = -59.9m USD (from netDebt column, last quarter)
Enterprise Value = 9.15b USD (9.21b + Debt 688.9m - CCE 748.7m)
Interest Coverage Ratio = 0.59 (Ebit TTM 26.1m / Interest Expense TTM 44.3m)
EV/FCF = 85.94x (Enterprise Value 9.15b / FCF TTM 106.5m)
FCF Yield = 1.16% (FCF TTM 106.5m / Enterprise Value 9.15b)
FCF Margin = 15.04% (FCF TTM 106.5m / Revenue TTM 707.9m)
Net Margin = 0.25% (Net Income TTM 1.74m / Revenue TTM 707.9m)
Gross Margin = 45.38% ((Revenue TTM 707.9m - Cost of Revenue TTM 386.6m) / Revenue TTM)
Gross Margin QoQ = 53.24% (prev 49.98%)
Tobins Q-Ratio = 3.13 (Enterprise Value 9.15b / Total Assets 2.92b)
Interest Expense / Debt = 3.98% (Interest Expense 27.4m / Debt 688.9m)
Taxrate = 12.86% (2.20m / 17.1m)
NOPAT = 22.8m (EBIT 26.1m * (1 - 12.86%))
Current Ratio = 8.36 (Total Current Assets 1.10b / Total Current Liabilities 131.1m)
Debt / Equity = 0.33 (Debt 688.9m / totalStockholderEquity, last quarter 2.08b)
Debt / EBITDA = -0.45 (Net Debt -59.9m / EBITDA 133.8m)
Debt / FCF = -0.56 (Net Debt -59.9m / FCF TTM 106.5m)
Total Stockholder Equity = 2.03b (last 4 quarters mean from totalStockholderEquity)
RoA = 0.06% (Net Income 1.74m / Total Assets 2.92b)
RoE = 0.09% (Net Income TTM 1.74m / Total Stockholder Equity 2.03b)
RoCE = 1.02% (EBIT 26.1m / Capital Employed (Equity 2.03b + L.T.Debt 537.9m))
RoIC = 0.89% (NOPAT 22.8m / Invested Capital 2.56b)
WACC = 10.75% (E(9.21b)/V(9.90b) * Re(11.29%) + D(688.9m)/V(9.90b) * Rd(3.98%) * (1-Tc(0.13)))
Discount Rate = 11.29% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 100.0 | Cagr: 0.63%
[DCF Debug] Terminal Value 72.87% ; FCFF base≈116.4m ; Y1≈143.6m ; Y5≈244.5m
Fair Price DCF = 47.99 (EV 2.64b - Net Debt -59.9m = Equity 2.70b / Shares 56.3m; r=10.75% [WACC]; 5y FCF grow 25.0% → 2.90% )
EPS Correlation: -75.41 | EPS CAGR: -53.93% | SUE: -3.52 | # QB: 0
Revenue Correlation: -40.77 | Revenue CAGR: 0.33% | SUE: 2.60 | # QB: 3
EPS next Quarter (2026-03-31): EPS=0.44 | Chg30d=-0.001 | Revisions Net=+0 | Analysts=15
EPS next Year (2026-12-31): EPS=2.08 | Chg30d=-0.006 | Revisions Net=-1 | Growth EPS=+24.4% | Growth Revenue=+12.5%